Grifols SA banner

Intrinsic Value

The intrinsic value of Grifols SA (G0FB) under the Base Case is 9.96 EUR per share. Compared with the current market price of 7.6 EUR, the stock appears Undervalued by 24% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

G0FB Intrinsic Value
€9.96
Undervaluation 24%
Intrinsic Value
Price €7.6

G0FB is valued in line with its history. A discount of this size has been typical over the past 5 years.

Monitor G0FB
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €7.97
Get notified when the price drops into your buy zone
Intrinsic Value €9.96
Margin of Safety 20% €7.97
Current Price €7.6
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to G0FB

Fundamental Analysis

What Grifols Does

Biotechnology Health Care

Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.

Headquarters
Spain ES
Employees
25 000
IPO date
May 17, 2006
Read the full company overview
View Company Overview

Grifols has no economic moat

No Moat Narrow Wide

Grifols SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Grifols SA

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one G0FB stock?

The intrinsic value for Grifols SA (G0FB) under the Base Case is 9.96 EUR.

Is G0FB stock undervalued or overvalued?

Compared with the current market price of 7.6 EUR, the stock appears Undervalued by 24% .

Back to Top